Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
Performance · Bacterial coinfectionResult — go to the resultOdds ratio 2 95% CI 1.25–3.19Authors' conclusion
Our study suggests that measurements of PCT and CRP, alone and at a single time point, are not useful for ruling in or out bacterial coinfection in viral pneumonia by COVID-19.
Study context
- Population
- Consecutive COVID-19 pneumonia patients admitted to 55 Spanish intensive care units (ICUs), 5 February 2020–21 December 2021133 (3%) bacterial coinfection
- Participants
- 4,076 patients
- Comparison
- Procalcitonin (PCT) vs C-reactive protein (CRP) upon hospital admission to identify bacterial coinfection
- Outcome
- Prediction of bacterial coinfection by PCT or CRP serum levels upon hospital admission
Methodological detailsmulticentre, observational cohort, consecutive patients
- Multicentre
- Observational cohort
- Consecutive patients
Performance
Bacterial coinfection
Odds ratio
2
95% CI 1.25–3.19
P = 0.004
By group
PCT
- AUC
- 0.57 (95% CI 0.51-0.61)
- NPV
- 97.5% (95% CI 96.5-98.5)
CRP
- AUC
- 0.6 (95% CI, 0.55-0.64)
- NPV
- 98.2% (95% CI 97.5-98.9)
AUC
PCT0.57 (95% CI 0.51-0.61)
CRP0.6 (95% CI, 0.55-0.64)
NPV
PCT97.5% (95% CI 96.5-98.5)
CRP98.2% (95% CI 97.5-98.9)
PCT vs CRP upon hospital admission to identify bacterial coinfection
OR 2 (95% CI 1.25–3.19); P = 0.004
As reported in the abstract
Secondary outcomes
15, 30 and 90 days mortality, bacterial coinfection vs not
- Higher trend in the bacterial coinfection group, without significant difference
90 days mortality by PCT
- PCT ≥ 0.12 ng/mL associated with higher 90 days mortality
Original publication
Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients. Intensive Care Med. Published 28 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →